Contents
Download PDF
pdf Download XML
376 Views
224 Downloads
Share this article
Research Article | Volume 11 Issue :4 (, 2021) | Pages 13 - 20
New Oral Anticoagulants in Antiphospholipid Syndrome Treatment
Under a Creative Commons license
Open Access
DOI : 10.5083/ejcm
Published
Dec. 25, 2021
Abstract

morbidity in the presence of persistent antiphospholipid antibodies. Current therapeutic recommendations for thrombosis prevention in patients with APS are limited to anticoagulation with Vitamin K Antagonists (VKA) or heparins and to anti-platelet aggregating agents. Maintaining optimized anticoagulation to prevent recurrent thrombosis or bleeding remains a therapeutic challenge. Direct Oral Anticoagulants (DOACs) DOACs have been approved to prevent recurrent thrombotic events in different prothrombotic conditions, such as non- valvular atrial fibrillation, deep vein thrombosis still aim the same target and thromboprophylaxis after elective orthopedic surgery.

Keywords
Recommended Articles
Research Article
Clinico-Demographic Profile, Angiographic Characteristics, and Procedural Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) with Three or More Coronary Stents: A Mixed-Design Cohort Study.
...
Published: 15/10/2025
Download PDF
Research Article
Role of 68Ga-DOTANOC PET/CT in the detection of Neuroendocrine Tumors
Published: 14/10/2025
Download PDF
Research Article
A Prospective, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Intravenous Dexmedetomidine on Spinal Bupivacaine Anaesthesia in Lower Abdominal Surgery
...
Published: 15/10/2025
Download PDF
Research Article
Clinicopathological and Immunohistochemical Profile of Primary Lung Carcinomas Diagnosed on Small Biopsy Specimens: A Cross-Sectional Observational Study.
...
Published: 30/05/2025
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.